AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
San Francisco, California--(Newsfile Corp. - January 28, 2025) - AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six ...
The probe conducted by China regulators, which reportedly centers on allegations that AstraZeneca employees improperly imported cancer medications like Enhertu and Imjudo from Hong Kong into ...
AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of its president in the country.
Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.
Jan 17 (Reuters) - AstraZeneca (AZN.L), opens new tab has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times ...
AstraZeneca (NASDAQ:AZN) has changed several key management positions in its China business as the Anglo-Swedish drugmaker looks to boost its sales following the recent detention of its President ...
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced ...
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
The probe conducted by China regulators, which reportedly centers on allegations that AstraZeneca employees improperly imported cancer medications like Enhertu and Imjudo from Hong Kong into ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and ...